GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes: A Narrative Review of Clinical Effectiveness, Safety, And Future Directions

• Author(s): Harry S Patel
• Paper ID: 1719510
• Page: 1315-1328
• Published Date: 31-12-2024
• Published In: Iconic Research And Engineering Journals
• Publisher: IRE Journals
• e-ISSN: 2456-8880
• Volume/Issue: Volume 8 Issue 6 December-2024
• DOI: https://doi.org/10.64388/IREV8I6-1719510

Abstract

Background: Since they were first discovered as a glucose-lowering drug, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have developed into drugs with significant impacts on weight loss and cardiorenal protection in the treatment of type 2 diabetes mellitus. This huge increase in evidence coupled with the emergence of dual incretin agonism calls for a comprehensive integration. Objective: To assess the clinical efficacy of the GLP-1 RAs and the dual GLP-1 and GIP receptor agonist tirzepatide in the domains of glycaemic, weight and cardiorenal clinical outcomes in type 2 diabetes and obesity; to review their safety profile; and to suggest future directions for the use of the class. Methods: This review is written in the fashion of a narrative review, combining data from 20 landmark and key { }randomized controlled trials (RCTs) and meta-analyses from cardiovascular outcome trials (CVOTs), weight-management trials and head-to-head comparisons published from 2016 to 2023. Results: All GLP-1 RAs have a proven ability to lower HbA1c consistently and to decrease body weight, and some agents have been proven to decrease major adverse cardiovascular events and renal outcomes in type 2 diabetes. Semaglutide is associated with reduction in cardiovascular events in obesity without diabetes and tirzepatide has had unprecedented reduction in glycaemic and weight status in head-to-head and placebo-controlled trials. The gastrointestinal side effect profile prevails, and low intrinsic hypoglycaemia risk. Conclusion: GLP-1 RAs and dual incretin agonists have come into a new role in the management of type 2 diabetes and obesity providing metabolic and cardiorenal benefit. New product development activities involve oral formulations, new multi-agonists and new indications that are not related to glycaemia and weight.

Keywords

GLP-1 Receptor Agonists, Type 2 Diabetes, Obesity, Tirzepatide, Semaglutide, Cardiovascular Outcomes, Narrative Review

Citations

IRE Journals:
Harry S Patel "GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes: A Narrative Review of Clinical Effectiveness, Safety, And Future Directions" Iconic Research And Engineering Journals Volume 8 Issue 6 2024 Page 1315-1328 https://doi.org/10.64388/IREV8I6-1719510

IEEE:
Harry S Patel "GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes: A Narrative Review of Clinical Effectiveness, Safety, And Future Directions" Iconic Research And Engineering Journals, vol. 8, no. 6, Dec. 2024, doi: https://doi.org/10.64388/IREV8I6-1719510

APA:
Harry S Patel (2024). GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes: A Narrative Review of Clinical Effectiveness, Safety, And Future Directions. Iconic Research And Engineering Journals, 8(6). doi: https://doi.org/10.64388/IREV8I6-1719510

MLA:
Harry S Patel "GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes: A Narrative Review of Clinical Effectiveness, Safety, And Future Directions" Iconic Research And Engineering Journals, vol. 8, no. 6, Dec. 2024. Crossref, https://doi.org/10.64388/IREV8I6-1719510

BibTeX

@article{1719510,
author = {Harry S Patel},
title = {GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes: A Narrative Review of Clinical Effectiveness, Safety, And Future Directions},
journal = {Iconic Research And Engineering Journals},
year = {2024},
volume = {8},
number = {6},
pages = {1315-1328},
issn = {2456-8880},
url = {https://www.irejournals.com/formatedpaper/1719510.pdf},
abstract = {Background: Since they were first discovered as a glucose-lowering drug, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have developed into drugs with significant impacts on weight loss and cardiorenal protection in the treatment of type 2 diabetes mellitus. This huge increase in evidence coupled with the emergence of dual incretin agonism calls for a comprehensive integration. Objective: To assess the clinical efficacy of the GLP-1 RAs and the dual GLP-1 and GIP receptor agonist tirzepatide in the domains of glycaemic, weight and cardiorenal clinical outcomes in type 2 diabetes and obesity; to review their safety profile; and to suggest future directions for the use of the class. Methods: This review is written in the fashion of a narrative review, combining data from 20 landmark and key { }randomized controlled trials (RCTs) and meta-analyses from cardiovascular outcome trials (CVOTs), weight-management trials and head-to-head comparisons published from 2016 to 2023. Results: All GLP-1 RAs have a proven ability to lower HbA1c consistently and to decrease body weight, and some agents have been proven to decrease major adverse cardiovascular events and renal outcomes in type 2 diabetes. Semaglutide is associated with reduction in cardiovascular events in obesity without diabetes and tirzepatide has had unprecedented reduction in glycaemic and weight status in head-to-head and placebo-controlled trials. The gastrointestinal side effect profile prevails, and low intrinsic hypoglycaemia risk. Conclusion: GLP-1 RAs and dual incretin agonists have come into a new role in the management of type 2 diabetes and obesity providing metabolic and cardiorenal benefit. New product development activities involve oral formulations, new multi-agonists and new indications that are not related to glycaemia and weight. },
keywords = {GLP-1 Receptor Agonists, Type 2 Diabetes, Obesity, Tirzepatide, Semaglutide, Cardiovascular Outcomes, Narrative Review},
month = {December}
}